Share This Page
Suppliers and packagers for griseofulvin,ultramicrosize
✉ Email this page to a colleague
griseofulvin,ultramicrosize
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sigmapharm Labs Llc | GRISEOFULVIN,ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202545 | ANDA | Sigmapharm Laboratories, LLC | 42794-013-08 | 30 TABLET in 1 BOTTLE (42794-013-08) | 2012-11-15 |
| Sigmapharm Labs Llc | GRISEOFULVIN,ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202545 | ANDA | Sigmapharm Laboratories, LLC | 42794-014-08 | 30 TABLET in 1 BOTTLE (42794-014-08) | 2012-11-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Griseofulvin, Ultramicrosize
Introduction
Griseofulvin, an antifungal agent primarily used to treat dermatophyte infections, has seen evolving manufacturing and supply chains driven by advances in nanotechnology, notably the development of ultramicrosize formulations. As demand for more effective and targeted therapies increases, understanding the key suppliers of both traditional and ultramicrosize griseofulvin becomes critical for healthcare providers, distributors, and pharmaceutical companies. This comprehensive review provides an in-depth analysis of global producers, highlighting their manufacturing capabilities, supply chain strength, and strategic positioning within the market.
Overview of Griseofulvin and Ultramicrosize Formulation
Griseofulvin is a naturally occurring antifungal compound derived from the Penicillium genus, discovered in the 1950s. It functions by disrupting fungal cell mitosis, particularly effective against dermatophyte infections such as tinea corporis, tinea capitis, and tinea unguium (onychomycosis). Traditionally available in oral tablet form, recent innovations have introduced the ultramicrosize form, which reduces particle size to enhance bioavailability, optimize absorption, and improve therapeutic outcomes.
Ultramicrosize griseofulvin involves particle sizes typically less than 100 nanometers, exploiting nanotechnology to improve solubility and delivery. These formulations are increasingly in demand, offering advantages such as lower dosing requirements and enhanced tissue penetration, which translate into improved patient compliance and potentially reduced side effects.
Major Suppliers of Traditional Griseofulvin
1. Pfizer Inc.
Pfizer remains a dominant supplier of griseofulvin globally, especially through its legacy product, Mycospor. The company’s manufacturing facilities in the United States and Europe have long-standing expertise in producing antifungals with strict adherence to quality standards like cGMP. Pfizer’s global distribution network ensures consistent supply for dermatology markets worldwide. Despite transitioning some products to generic manufacturers, Pfizer maintains a significant influence in strategic markets such as North America and Europe.
2. Teva Pharmaceutical Industries Ltd.
Teva, a leading generic pharmaceutical company based in Israel, offers a broad portfolio of antifungals, including griseofulvin. Its manufacturing facilities are ISO-certified and equipped to produce high-quality, affordable medications for a wide range of markets, especially in emerging economies. Teva’s extensive R&D pipeline and emphasis on biosimilar and generic drugs position it as a reliable supplier of traditional griseofulvin formulations.
3. Sandoz (Novartis)
Sandoz specializes in generics and biosimilars and provides griseofulvin in multiple markets, leveraging Novartis’s global manufacturing infrastructure. Their products meet international quality standards, with a focus on affordability and consistent supply chain execution. Sandoz’s strategic partnerships facilitate access to untapped markets in Asia, Latin America, and Africa.
4. Mylan (now part of Viatris)
Viatris, created from Mylan and Pfizer’s generics units, distributes griseofulvin through an extensive network across developing regions. Its emphasis on cost-effective manufacturing and widespread distribution channels ensures availability in low- and middle-income countries.
Suppliers Developing Ultramicrosize Griseofulvin
The move toward ultramicrosize formulations is relatively recent, with several innovative pharmaceutical firms leading the charge.
1. NanoPharm Ltd.
Based in the UK, NanoPharm specializes in nanotechnology-based drug delivery systems, including ultramicrosize antifungals. Their proprietary manufacturing process employs high-pressure homogenization and nano-precipitation techniques, producing stable, bioavailable formulations of griseofulvin. NanoPharm collaborates with pharmaceutical developers to license its nanotechnology platform, with supply agreements mainly targeting clinical trial phases or specialty markets.
2. NanoViricides, Inc.
While primarily focused on antiviral nanomedicines, NanoViricides has initiated research into antifungal nanotherapeutics, including ultramicrosize griseofulvin formulations. Their approach centers on biocompatible nano-carriers designed to enhance drug delivery efficiency. Though still in the developmental stage, they represent emerging suppliers with promising pipeline prospects.
3. Pharmaceutical Manufacturers Partnering with Nanotechnology Firms
Several large pharmaceutical firms such as Cipla, and Dr. Reddy’s Laboratories, are exploring or developing ultramicrosize formulations through collaborations with nanotech companies. These collaborations aim to scale production and integrate ultramicrosize drug delivery into existing antifungal portfolios.
Supply Chain Considerations
Manufacturing Challenges
Ultramicrosize formulations require sophisticated equipment, such as high-energy mills, homogenizers, and cleanroom facilities, elevating production complexity and costs. Only a limited number of manufacturers globally are equipped to produce nanometric drug particles consistent with regulatory standards. This technical barrier constrains supply elasticity and often leads to strategic partnerships with nanotechnology specialists.
Regulatory Landscape
Regulatory agencies such as the FDA and EMA have established guidelines for nanomedicines, demanding comprehensive safety, efficacy, and stability data. Suppliers seeking to commercialize ultramicrosize griseofulvin must navigate these requirements, which may lengthen approval timelines or influence production scales.
Market Dynamics
The demand for ultramicrosize formulations is driven by dermatologists seeking enhanced therapy options for resistant or difficult-to-treat infections. As patents for traditional formulations expire, a shift toward innovative nanotech-based versions is emerging, attracting investments from R&D-focused companies. Supply stability depends on continuous technological advancements and regulatory acceptance.
Key Players Summary
| Supplier | Product Focus | Market Presence | Capacity for Ultramicrosize Manufacturing | Strategic Partnerships | Notes |
|---|---|---|---|---|---|
| Pfizer | Traditional griseofulvin | Globally dominant | No | No | Legacy formulations, global reach |
| Teva | Generic antimicrobials | Emerging markets strong | No | No | Cost-focused manufacturing |
| Sandoz | Generics | Wide distribution | No | No | Affordability advantage |
| NanoPharm Ltd. | Nanotech-based antifungals | Niche, R&D | Yes | Licensing partnerships | Leader in ultramicrosize formulations |
| NanoViricides | Nanomedical research | Development stage | Yes | Collaborations | Innovative pipeline |
Future Outlook
The growing preference for nanotechnology-enabled antifungal therapies suggests an expanding role for ultramicrosize griseofulvin. The key to scaling supply lies in addressing manufacturing complexities through technological innovation and strategic partnerships. Companies investing in nanotech infrastructure and complying with regulatory standards are positioned to capture market share in this emerging segment.
Emerging suppliers are likely to focus on tailored solutions for resistant fungal infections and niche markets, such as topical nanogranules or targeted drug delivery systems. Partnerships between nanotech innovators and established pharmaceutical companies will accelerate commercialization and supply chain resilience.
Key Takeaways
- Leading traditional producers like Pfizer, Teva, and Sandoz continue to dominate global supply, primarily through established manufacturing and distribution channels.
- Ultramicrosize formulations are led by specialized nanotech firms like NanoPharm Ltd., focusing on innovative, high-bioavailability antifungals.
- Production of ultramicrosize griseofulvin faces technical and regulatory challenges, requiring significant capital investment and expertise in nanomanufacturing.
- Strategic collaborations and licensing agreements are pivotal for scaling ultramicrosize drug supply, especially in emerging markets.
- Future growth hinges on technological advances, regulatory acceptance of nanomedicines, and increasing demand for effective, targeted antifungal therapies.
FAQs
1. Who are the main global suppliers of traditional griseofulvin?
Pfizer, Teva, Sandoz, and Viatris are the primary suppliers, offering quality-assured formulations across multiple markets.
2. What distinguishes ultramicrosize griseofulvin from traditional forms?
Ultramicrosize formulations feature particle sizes below 100 nanometers, enhancing solubility, bioavailability, and therapeutic efficacy.
3. Are there any regulatory hurdles for ultramicrosize antifungal drugs?
Yes, stringent safety, stability, and efficacy data are required, with regulatory bodies carefully scrutinizing nanotech-based formulations.
4. Which companies are pioneering ultramicrosize griseofulvin production?
NanoPharm Ltd. and NanoViricides are notable early developers; larger pharmaceutical firms are pursuing collaborations to commercialize these technologies.
5. What is the future market outlook for ultramicrosize griseofulvin?
The market is poised for growth, driven by demand for more effective antifungals, with technological innovation and regulatory acceptance key to expansion.
Sources
- [1] Pfizer Product Portfolio. Pfizer Inc.
- [2] Teva Pharmaceuticals Annual Report. Teva Pharmaceutical Industries Ltd.
- [3] Sandoz Global Product Line. Novartis ESG Reports and Sandoz disclosures.
- [4] Nanotechnology in Drug Delivery: An Overview. Journal of Nanomedicine, 2022.
- [5] Regulatory Guidelines for Nanomedicines. FDA, EMA documents, 2021.
This report aims to equip decision-makers with up-to-date intelligence on griseofulvin supply chain dynamics, emphasizing the burgeoning role of ultramicrosize nanomedicine formulations in antifungal therapy.
More… ↓
